This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
The name 'vascular hemophilia (Angiohaemophilia)' is one of the historical names for von Willebrand disease (vWD) and originated from early investigators understanding the bleeding mechanism of this disease as 'an abnormality of vascular components'. This term is now officially listed in ICD-10 code D68.0 as a synonym in parentheses, "von Willebrand disease (vascular haemophilia)", and in actual clinical practice the disease is mainly referred to as 'von Willebrand disease'.
When Erik Adolf von Willebrand (1870-1949) first examined a 5-year-old girl named Hjördis from the Åland Islands of Finland in 1924, he noted that the bleeding time was markedly prolonged despite a normal platelet count and normal coagulation tests. This finding was clearly different from hemophilia as then known (a coagulation disorder due to FVIII or FIX deficiency). Von Willebrand inferred that this abnormality lay not in platelets or coagulation factor levels but in the vessel wall or the interaction at the vessel-platelet interface, and accordingly described the disease as 'hereditary pseudohemophilia (Hereditäre Pseudohämophilie)' or 'vascular hemophilia (vaskuläre Hämophilie)'.
Von Willebrand's intuition about this 'vascular' aspect turned out to be partly correct. As revealed decades later, von Willebrand factor (vWF) is a protein of endothelial origin that is stored in the Weibel-Palade bodies of vascular endothelial cells, is released at the time of vascular injury, binds to subendothelial collagen, and captures platelets. Therefore, in that vWF deficiency presents as a functional abnormality of the vessel-platelet interface, the name 'vascular hemophilia' partly reflected the core pathophysiology.
However, the name 'vascular hemophilia' could give rise to the misunderstanding that there is an abnormality of the vascular structure itself (vessel wall, angiogenesis). Subsequently, through the work of Jorpes and Blombäck in 1953 and of Zimmermann, Ratnoff, and Powell in 1971, vWF was identified as an independent protein, and with the cloning of the VWF gene in 1986, it was clearly established that this disease is a deficiency or dysfunction of a specific protein (vWF) rather than an abnormality of vascular structure.
'Angiohaemophilia' is a compound of the Greek angio (vessel) and haemophilia (bleeding tendency), and carries the meaning of a bleeding tendency related to vascular components. This name was used mainly in English-language medical literature from the 1950s to the 1970s, was used together with 'pseudohemophilia (pseudohemophilia A)' or 'vascular hemophilia', and gradually disappeared. It is now a term that survives only in historical literature and the ICD classification system.
After von Willebrand's first report in 1926, the history of this disease continued into the era of full-scale mechanistic research. In 1957, von Willebrand published the results of long-term follow-up of the Åland Islands family, reporting that in the interim 4 people in the family, including Hjördis, had died of bleeding related to this disease. This tragic case imprinted the clinical severity of this disease on the world medical community.
In the 1950s and 1960s, the relationship between this disease and coagulation factors began to be elucidated. Investigators at the time found that FVIII coagulant activity (FVIII:C) was sometimes low in patients with this disease, and at first tried to understand the disease as a variant of hemophilia A (FVIII deficiency). In 1953, Jorpes and Blombäck provided a clue that a separate factor binding FVIII exists in plasma, and this became the beginning of elucidating the FVIII carrier function of vWF.
In 1971, Zimmermann, Ratnoff, and Powell developed an immunological method to measure vWF antigen (vWF:Ag) in plasma, making it possible to measure vWF:Ag and FVIII:C separately. This made it possible for the first time to distinguish laboratory-wise between classical hemophilia A (decreased FVIII:C, normal vWF:Ag) and vWD (decreased vWF:Ag or dysfunction). These results became decisive evidence, at the laboratory level, that 'vascular hemophilia' is in effect a deficiency or dysfunction of the FVIII carrier protein (vWF).
In the 1980s, elucidation of the vWF multimer structure, classification of type 2 subtypes, demonstration of the therapeutic effect of DDAVP in 1982, and cloning of the VWF gene in 1986 followed one after another. The various names discussed since the 1950s (vascular hemophilia, angiohaemophilia, pseudohemophilia, von Willebrand factor deficiency, etc.) were unified internationally as 'von Willebrand disease' through the 1980s and 1990s. This was to honor Erik von Willebrand, the discoverer of the disease, and at the same time to reflect directly in the name the molecular pathology of a specific protein deficiency.
The current ICD-10 code D68.0 preserves this historical name in the official record by stating "von Willebrand disease" as the main name and "(vascular haemophilia)" as a synonym in parentheses. The developments leading to the 2006 standardization of the vWD classification system by the ISTH SSC and the 2021 FDA approval of the first recombinant vWF product (vonicog alfa, Vonvendi) illustrate the history of this disease, which started under the name 'vascular hemophilia' and evolved into precision medicine at the molecular level.
Vascular haemophilia (= von Willebrand disease) is a hereditary bleeding disorder caused by various variants of the VWF gene (chromosome 12p13.3). The VWF gene consists of 52 exons over a length of 178kb, and the variants registered to date far exceed 1,000. It is important to understand that the name of this disease, 'vascular haemophilia', does not imply an abnormality of the vascular structure itself, but that the core cause is an abnormality of vessel-platelet interaction via vWF.
Type 1 is characterized by partial quantitative deficiency of vWF. vWF:Ag is generally decreased to a level of 30-50 IU/dL, and it arises from heterozygous variants (mainly missense, splicing, and nonsense variants). These variants lower plasma vWF levels through decreased vWF synthesis, defective assembly of Weibel-Palade bodies in endothelial cells, or premature degradation after secretion. The expressivity of type 1 is highly variable and is strongly influenced by external factors such as blood group O (vWF:Ag about 25% lower), pregnancy, age, and acute-phase response.
Type 2 is a qualitative defect of the vWF protein, mainly caused by missense variants in specific functional domains. In type 2A, A2 domain variants cause impaired formation of high-molecular-weight multimers or excessive cleavage by ADAMTS13. In type 2B, gain-of-function variants of the A1 domain cause abnormal high-affinity binding to platelet GPIbα. In type 2M, A1 or A3 domain variants reduce platelet and collagen binding capacity. In type 2N (Normandy type), D'-D3 domain variants abolish FVIII binding capacity and FVIII:C is decreased.
Type 3 is a state in which vWF is almost completely deficient owing to null variants of both alleles of the VWF gene (homozygous or compound heterozygous). Large deletions, nonsense variants, and frameshift variants predominate, and FVIII:C is also degraded rapidly without the protection of vWF and becomes markedly low. In type 3, alloantibodies against plasma-derived vWF products may rarely form.
Acquired vascular hemophilia is, unlike the hereditary form, a state in which vWF is functionally lost without VWF gene variants, due to autoantibodies (anti-vWF), excessive blood flow shear stress (aortic stenosis, ventricular assist devices, etc.), lymphoproliferative disorders, and so on. Treatment of the underlying disease takes priority, and the approach differs from that of the hereditary form.
The VWF gene is located on chromosome 12p13.3 and is a large gene with a length of 178kb and 52 exons. The transcript (mRNA) of the VWF gene is 8,439 nucleotides, and the precursor protein translated from it (pre-pro-vWF) consists of 2,813 amino acids. During intracellular processing, the signal peptide (22 amino acids) and the pro-peptide (741 amino acids) are cleaved to form the mature vWF monomer (2,050 amino acids, about 250 kDa). Mature monomers form multimers through N-terminal and C-terminal disulfide bonds, and giant multimers in which up to dozens of monomers are linked have a molecular weight exceeding 20,000 kDa.
In the functional domain structure of the vWF protein (D1-D2-D'-D3-A1-A2-A3-D4-B1-B2-B3-C1-C2-CK), each domain is responsible for specific interactions. D'-D3 binds FVIII, A1 binds platelet GPIbα and collagen (ristocetin-dependent), A2 contains the ADAMTS13 cleavage site, A3 binds subendothelial collagen (types I and III), and C2/CK serve in GPIIb-IIIa binding. The fact that the clinical phenotype is determined by the location of the variant in each domain is the molecular basis of the subtype classification.
The mode of inheritance differs by type and subtype. Autosomal dominant inheritance is seen in type 1 and most type 2 (2A, 2B, 2M), and clinical symptoms can appear even in heterozygous carriers. Autosomal recessive inheritance is seen in types 2N and 3, and a marked phenotype is shown only in the homozygous or compound heterozygous state. Heterozygous carriers of type 2N have a 50% reduction in vWF:FVIII binding capacity but have mild or no clinical symptoms.
What is important in genetic counseling is the variability of expressivity. Even among family members with the same VWF variant, vWF:Ag levels and bleeding symptoms can differ markedly. This is because modifier genes, blood group, hormonal status, age, and so on affect vWF levels. In particular, blood group O is known to lower vWF:Ag because the ABO blood group antigens bound to vWF increase cleavage by ADAMTS13.
The VWF pseudogene (VWFP) located on chromosome 22 shows more than 97% sequence homology with the exon 23-34 region, so in genetic analysis of this region the pseudogene sequence may be co-amplified and false-positive variants may be found. Therefore, specific analysis using long-range PCR or NGS is necessary when analyzing this region.
Vascular haemophilia (= von Willebrand disease) is the most common hereditary bleeding disorder reported worldwide. In studies of the general population, the carrier rate of clinically significant variants of the VWF gene is estimated at about 1%, but the prevalence of patients who actually have bleeding symptoms and are diagnosed at medical institutions is estimated at about 125 per million. The difference between the diagnosis rate and the actual prevalence is because in mild (type 1) patients the symptoms are mild, so they often go undiagnosed or are mistaken for other diseases.
The sex distribution is theoretically equal (autosomal inherited disease), but the reason a higher diagnosis rate is reported in women is that menorrhagia appears as a periodic and obvious bleeding symptom. In international studies, about 60-90% of female vWD patients experience menorrhagia, which leads to anemia, iron deficiency, and reduced quality of life. Men have an equal prevalence but lack a regular hemostatic challenge such as menstruation, so detection may be delayed.
By type, type 1 accounts for 70-80% of the total, type 2 about 15-20%, and type 3 is rare at about 1-3 per million. Because type 3 is autosomal recessive, its prevalence is relatively high in some communities with a high frequency of consanguineous marriage, such as Iran and India. Within type 2, type 2A is reported most often, followed by 2B, 2M, and 2N. Type 2N can be clinically confused with hemophilia A, so it may be underdiagnosed.
With regard to age, although vascular haemophilia is present from childhood, first diagnosis in adulthood is very common. Patients with type 1 often do not recognize their symptoms until they experience a hemostatic stress event such as a first surgery, tooth extraction, or childbirth. In Korea as well, according to rare disease Special Copayment Reduction (V009) registration statistics, the proportion of patients first diagnosed after adulthood is known to be considerable.
As the name vascular haemophilia suggests an 'abnormality of vascular components', the core pathophysiology of this disease is deficiency or dysfunction of von Willebrand factor (vWF), which is produced, stored, and secreted by vascular endothelial cells. vWF is stored in the Weibel-Palade bodies of vascular endothelial cells and the α-granules (alpha granules) of platelets, and is secreted into plasma in response to signals of vascular injury (DDAVP, thrombin, histamine, shear stress).
Secreted vWF binds through the A3 domain to the subendothelial matrix exposed at the site of vascular injury (collagen, especially types I, III, and VI) and forms a platelet-capturing matrix. After collagen binding, vWF unfolds under fluid shear force and exposes the A1 domain, and this A1 domain binds the GP Ib-IX-V complex (GPIbα) on the platelet surface, thereby capturing platelets at the site of vascular injury. This is the key step of primary hemostasis. When vWF is deficient or A1/A3 domain function is reduced, this platelet capture step is insufficient and formation of the hemostatic plug is impaired.
In high-shear blood flow environments in particular (arteries, arterioles, narrow vessels), the GPIbα binding capacity of vWF is essential for platelet adhesion. In this environment, fibrinogen and other adhesion molecules lack the ability to attach platelets, and only vWF multimers can function sufficiently. Because high-molecular-weight multimers (HMW multimers) perform this role most efficiently, the bleeding tendency is especially severe in types 2A and 2B, in which HMW multimers are lost.
The second key function of vWF is stabilization of FVIII in plasma. vWF binds non-covalently to the C2 domain of FVIII through the D'-D3 domain, protecting FVIII from proteases (FXa, APC, plasmin, etc.) and prolonging its half-life. When vWF is deficient, FVIII is degraded prematurely in plasma and FVIII:C is decreased. In type 3, by this mechanism FVIII:C falls below 10 IU/dL, and severe bleeding accompanied even by a coagulation disorder occurs.
ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin motifs 13) is an enzyme that regulates the size of vWF multimers in plasma and cleaves the Tyr1605-Met1606 bond of the vWF A2 domain. Normally this enzyme degrades ultra-large multimers (UL-vWF) and suppresses thrombus formation. In some cases of type 2A, A2 domain variants cause excessive cleavage by ADAMTS13 and loss of high-molecular-weight multimers.
The clinical symptoms of vascular haemophilia range from mild to severe depending on the degree and type of vWF deficiency. The most characteristic symptom is mucocutaneous bleeding, which reflects that vWF is a protein of the primary hemostasis stage involved in vessel-platelet interaction.
The most common symptom is epistaxis (nosebleed). It occurs with minor stimulation or spontaneously and is characterized by difficulty achieving hemostasis; recurrent epistaxis is an important clue for suspecting vWD. Gingival bleeding, skin bruising (easily occurring, widely spreading pattern), gastrointestinal bleeding, and genitourinary bleeding may also occur. In type 1 these symptoms are mild, so in childhood the child is regarded merely as 'one who bruises easily', and there are many cases first diagnosed in adulthood on the occasion of surgery or tooth extraction.
In women, menorrhagia is one of the most important symptoms of vascular haemophilia. The typical pattern is frequent pad/tampon changes, accompanying clots, and menstruation lasting 7 days or more. Chronic iron deficiency anemia resulting from this is also commonly present. During pregnancy vWF rises physiologically and bleeding symptoms may transiently improve, but immediately after delivery vWF levels fall sharply to normal or below, and postpartum hemorrhage can occur. This is a risk factor that must be considered in establishing a delivery plan.
Delayed hemostasis or excessive bleeding may appear after invasive procedures such as surgery, tooth extraction, and endoscopic biopsy. In particular, bleeding after tonsillectomy and adenoidectomy is a representative presentation of vWD, and rebleeding (delayed bleeding) 5-10 days after surgery, rather than immediately after surgery, is characteristic.
In type 2N (Normandy type), owing to a marked decrease in FVIII:C, joint bleeding (hemarthrosis) or deep muscle bleeding may occur, which is clinically similar to X-linked hemophilia A. However, type 2N provides important clues that distinguish it from hemophilia A: it is inherited in an autosomal recessive manner and affects men and women equally, and the mother (a carrier) can also show bleeding symptoms.
In type 3, owing to complete deficiency of vWF and severe reduction of FVIII:C (below 10 IU/dL), life-threatening severe bleeding such as spontaneous joint bleeding, muscle hematomas, recurrent arthropathy (hemophilic arthropathy), and central nervous system bleeding occurs. Arthropathy can lead to chronic pain, joint deformity, and limited movement.
On physical examination of vascular haemophilia, signs of mucosal bleeding (nasal mucosal vascular dilatation, gum bleeding), extensive bruising (ecchymosis), hematomas (hemarthrosis or muscle hematoma, mainly types 3 and 2N), and pallor due to chronic bleeding (anemia) may be observed. However, diagnosis is difficult from physical examination findings alone, and specific laboratory findings are key.
On basic blood coagulation tests, PT (prothrombin time) is normal, and APTT (activated partial thromboplastin time) is prolonged only when FVIII:C is markedly low (types 3 and 2N). In mild type 1 and type 2, APTT may be in the normal range, so its sensitivity as a screening test is low. The platelet count is mostly normal, but in type 2B mild to moderate thrombocytopenia may accompany.
PFA-100/PFA-200 (platelet function analyzer) is currently used as the standard screening tool. It measures the time (closure time, CT) for platelets to occlude a collagen-ADP or collagen-epinephrine membrane under high-shear conditions, and CT is prolonged in vWF deficiency. The PFA-200 measures under higher shear conditions and is reported to be more sensitive for detecting mild vWD.
The following are important as specific test findings: decreased vWF:Ag (ELISA or immunoturbidimetric assay, reference range 50-150 IU/dL); decreased vWF:RCo (ristocetin cofactor activity) or vWF:GPIbM; decreased FVIII:C (mainly types 2N and 3); vWF:RCo/vWF:Ag ratio <0.7 (suggests type 2). On vWF multimer electrophoresis, types 2A and 2B show loss of high-molecular-weight multimers, types 2M, 2N, and 1 show an overall decrease or normal pattern, and type 3 shows loss of all multimers. On RIPA (ristocetin-induced platelet aggregation), type 2B shows a characteristic finding of abnormal aggregation at low-concentration ristocetin (0.5-0.7 mg/mL).
Screening for vascular haemophilia begins with systematic bleeding history taking. Using the Bleeding Assessment Tool (BAT) of the International Society on Thrombosis and Haemostasis (ISTH), items such as epistaxis, gum bleeding, bruising, heavy menstrual bleeding, bleeding after surgery, tooth extraction, and delivery, gastrointestinal bleeding, and hematuria are quantified. Further detailed testing is performed if the score is ≥3 in adult men, ≥5 in women, and ≥2 in children. Beyond its role as a screening tool, the BAT is also useful for objective recording of bleeding severity and tracking of treatment course.
The first step of laboratory screening is PFA-100/200 (platelet function analyzer). This test can screen for vWF dysfunction and platelet dysfunction at the same time, but has the limitation that false negatives can occur in mild type 1 (vWF:Ag 40-50 IU/dL). APTT is prolonged only when FVIII:C is low, so it is likely to be normal in type 1 and type 2. A decreased platelet count can be a clue suggesting type 2B.
When an abnormality is found on screening tests, or the bleeding history strongly suggests vWD, specific vWD testing is carried out. Important points to consider beforehand are whether the patient has blood group O (low vWF:Ag, beware of false-positive diagnosis), is pregnant (false negatives possible owing to physiological rise of vWF), is taking estrogen preparations (vWF may rise), or is in an acute inflammation or stress state (vWF may rise). In these situations, repeat testing should be performed at a stable time, or these factors must be taken into account when interpreting the results.
Definitive diagnosis of vascular haemophilia is made by a combination of the following specific tests. It is difficult to make a definitive diagnosis from a single test alone, and clinical history, family history, and laboratory findings must be judged comprehensively.
vWF:Ag: Measured by ELISA or immunoturbidimetric assay (LIA). Normal reference range 50-150 IU/dL. Decreased in types 1 and 3, and variable in type 2, from normal to mildly decreased. The 30-50 IU/dL range is treated as 'low VWF', a borderline zone between vWD type 1 and normal variation, and clinical judgment is important.
vWF:RCo or vWF:GPIbM: Evaluates the platelet binding function of vWF (A1 domain function). vWF:RCo is the traditional method that measures vWF binding to fixed platelets in the presence of ristocetin, and vWF:GPIbM is a standardized method using a recombinant GPIbα fragment with high reproducibility. A vWF:RCo (or vWF:GPIbM)/vWF:Ag ratio below 0.7 suggests a type 2 qualitative defect.
FVIII:C: Measured by one-stage clotting assay or chromogenic substrate method. Markedly decreased in types 2N and 3 (about 5-30 IU/dL and 1-10 IU/dL, respectively). A low FVIII:C/vWF:Ag ratio in type 2N helps in differentiation from hemophilia A.
vWF multimer electrophoresis: Analysis of multimer distribution using SDS-agarose gel (0.5-2% concentration). Types 2A and 2B: loss of high-molecular-weight multimers; abnormal intermediate multimer band pattern (abnormal satellite bands). Types 2M, 2N, and 1: overall decrease or normal distribution. Type 3: loss of all multimers.
RIPA (ristocetin-induced platelet aggregation): Checks the aggregation response of the patient's platelets at various ristocetin concentrations. In type 2B, abnormally strong aggregation at low-concentration ristocetin (0.3-0.7 mg/mL) is the key diagnostic finding. In normal individuals and other vWD subtypes, there is no aggregation at low concentrations.
vWF:FVIII binding (vWF:FVIIIB): Evaluates the FVIII binding capacity of the D'-D3 domain. Essential for definitive diagnosis of type 2N, and decisive in differentiating hemophilia A (normal VWF, F8 gene variant) from type 2N (normal F8, VWF variant).
VWF NGS (next-generation sequencing): Analysis of the entire VWF gene, all 52 exons + intron splice junctions + 5'/3' UTR + promoter. To exclude contamination by the pseudogene (chromosome 22), long-range PCR-based NGS or specific amplicon methods are used. Used when subtype classification is uncertain, for carrier identification within the family, genetic counseling, and prenatal diagnosis.
Treatment of vascular haemophilia aims at prevention and control of bleeding, and an individualized approach is needed according to the vWD subtype, severity, and clinical situation. As the name 'vascular haemophilia' suggests, there is no direct treatment for vascular components; the key is to replace the deficient vWF or to release vWF stored within endothelial cells.
DDAVP (desmopressin) is the mainstay of treatment for type 1 vascular haemophilia. DDAVP is a synthetic arginine vasopressin (AVP) analog that activates V2 receptors on vascular endothelial cells to increase intracellular cAMP, thereby releasing vWF and tissue plasminogen activator (t-PA) stored in Weibel-Palade bodies into plasma. 30-60 minutes after administration, vWF:Ag and FVIII:C rise to 2-5 times baseline and last about 6-8 hours. It is given by intravenous injection (0.3 mcg/kg, 30-minute infusion), subcutaneous injection, or high-concentration nasal spray (Stimate 150 mcg/spray). With consecutive administration, tachyphylaxis (depletion of storage pools) occurs, so the dosing interval is kept at 48 hours or longer. It is contraindicated in type 2B because secreted vWF binds excessively to GPIbα and may worsen thrombocytopenia, and it is ineffective in type 3 because there is no stored vWF itself.
vWF concentrates are used when DDAVP is contraindicated or ineffective (types 2B and 3, DDAVP-nonresponsive type 2), for severe bleeding, major surgery, and prophylaxis. Plasma-derived products (Humate-P, Wilate, Alphanate, Beriate P) contain vWF and FVIII in various ratios and undergo viral inactivation treatment such as in-hospital pasteurization. Vonicog alfa (Vonvendi), approved by the FDA in 2021, is the first recombinant vWF product, produced in Chinese hamster ovary (CHO) cells; it does not contain FVIII, so recombinant FVIII can be added according to the FVIII level. The advantage of recombinant products is that there is no risk of blood-borne pathogens (viruses, prions, etc.). Target vWF:RCo levels: 80-100 IU/dL for surgery, 50-60 IU/dL for minor surgery and prophylaxis.
Tranexamic acid is an antifibrinolytic (lysine analog) that competitively inhibits the binding of plasminogen to fibrin, thereby blocking fibrinolysis. It is widely used as first-line or adjunctive treatment for mucosal bleeding such as epistaxis, gum bleeding, heavy menstrual bleeding, bleeding after tooth extraction, and gastrointestinal bleeding. It can be given orally (15-25 mg/kg, three times daily) or intravenously. It can be used alone or together with DDAVP/vWF concentrates, and caution is needed in genitourinary bleeding because of the risk of upper urinary tract clot obstruction.
Female-specific treatment: Combined oral contraceptives (estrogen + progesterone) have a dual effect of controlling heavy menstrual bleeding and increasing vWF synthesis. The levonorgestrel intrauterine device (LNG-IUD, Mirena) is also effective in controlling heavy menstrual bleeding. When iron deficiency anemia is present, iron supplementation is given concurrently.
Pregnancy and delivery: Regular monitoring of vWF levels during pregnancy (at 28 weeks, 34 weeks, and before delivery) is recommended, and DDAVP or vWF concentrates are given beforehand with the targets of vWF:RCo ≥50 IU/dL for delivery and ≥100 IU/dL for cesarean section. vWF levels may fall until 4 weeks postpartum, so monitoring and treatment when needed continue. Epidural anesthesia can be performed only when vWF/FVIII levels have been sufficiently corrected.
The prognosis of vascular haemophilia differs greatly by type and treatment approach. Patients with type 1 maintain a normal life expectancy with appropriate treatment and in many cases have no major limitation in daily life. Type 1 patients who respond well to DDAVP can effectively manage the bleeding risk in hemostatic challenge situations such as surgery and delivery by giving DDAVP in advance according to plan. As vWF levels tend to rise physiologically with age, symptoms may improve spontaneously in some elderly type 1 patients.
The prognosis of type 2 differs by subtype. Types 2A and 2B have a bleeding tendency of moderate or greater severity, so perioperative management is important, and most cases can be controlled with vWF concentrates. In type 2B, persistent thrombocytopenia is rarely a problem, but thrombocytopenia can worsen during pregnancy, so caution is needed in obstetric management. Type 2N has a good prognosis if FVIII:C is corrected with vWF-containing products. With recombinant FVIII alone, the FVIII half-life remains short owing to the absence of vWF and the effect may be insufficient, so the use of vWF-containing products is always recommended.
Type 3 is the most severe phenotype, and without prophylaxis serious complications such as joint bleeding, arthropathy, muscle atrophy, and central nervous system bleeding can occur. However, when regular prophylactic administration of vWF concentrates (prophylaxis) is carried out, joint damage can be effectively prevented and quality of life greatly improved. The rare formation of anti-vWF alloantibodies in type 3 can complicate treatment, and caution is needed because of the risk of anaphylactic reactions as well. In this case, switching to a recombinant vWF product or attempting immune tolerance induction is considered.
Overall, the factors with the greatest impact on the quality of life of patients with vascular haemophilia are repeated hospital treatment, chronic joint pain (type 3), persistent heavy menstrual bleeding, and psychological anxiety about bleeding events. Comprehensive management at a specialized hematology center, patient education, and psychological support are important for improving long-term prognosis.
Primary prevention of vascular haemophilia is risk assessment within the family through genetic counseling. Type 1 and type 2 (most) are autosomal dominant, so a patient's child has a 50% chance of inheriting the variant. Types 2N and 3 are autosomal recessive, and when both parents are carriers, 25% of children are affected. Carrier identification by molecular genetic testing is recommended for the patient's siblings and children, and pregnancy planning and prenatal diagnosis can be discussed based on the test results.
The key to secondary prevention is advance preparation for situations that provoke bleeding. Before any surgery, dental procedure (especially tooth extraction), endoscopic biopsy, or delivery, a consultation with a hematologist is essential to set target vWF/FVIII levels and establish a plan for giving DDAVP or vWF concentrates beforehand. In type 1 patients, it is important to perform a DDAVP response test (test dose) before the procedure to confirm each individual's response and magnitude of increase. Drugs that inhibit platelet function, such as aspirin, NSAIDs, and clopidogrel, should be avoided, and when unavoidable the hematologist should be consulted in advance.
For female patients, a menstrual management plan is established. Using treatment options such as combined oral contraceptives, tranexamic acid, and the LNG-IUD in a planned way according to the menstrual cycle can prevent anemia and decreased quality of life caused by heavy menstrual bleeding. For girls diagnosed before their first menstruation, it is recommended to establish a treatment plan before menstruation begins.
In patients with severe (type 3) and severe type 2 disease, prophylaxis has become the standard treatment. Regular administration of vWF concentrates (e.g., self-injection 2-3 times a week) can reduce the frequency of spontaneous bleeding and prevent joint damage. Based on experience with prophylaxis in hemophilia A, evidence is accumulating that prophylaxis in childhood and adolescence in type 3 vWD is effective for preventing long-term complications. For rapid treatment in an emergency, it is recommended to always carry a patient card (stating the vWD diagnosis, type, and treatment method) and to keep tranexamic acid and, if needed, DDAVP nasal spray at home.